

## CFC1 RABBIT PAB

货号: S221198

产品全名: CFC1 兔多抗

基因符号: HTX2; CFC1B; DTGA2; CRYPTIC

**UNIPROT ID:** P0CG37 (Gene Accession - NP\_115934)

**背景:** This gene encodes a member of the epidermal growth factor (EGF)- Cripto, Frl-1, and Cryptic (CFC) family, which are involved in signalling during embryonic development. Proteins in this family share a variant EGF-like motif, a conserved cysteine-rich domain, and a C-terminal hydrophobic region. The protein encoded by this gene is necessary for patterning the left-right embryonic axis. Mutations in this gene are associated with defects in organ development, including autosomal visceral heterotaxy and congenital heart disease. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

**抗原:** Synthetic peptide of human CFC1

**经过测试的应用:** ELISA, IHC

**推荐稀释比:** IHC: 25-100; ELISA: 2000-5000

**种属反应性:** Rabbit

**克隆性:** Rabbit Polyclonal

**亚型:** Immunogen-specific rabbit IgG


**纯化:** Antigen affinity purification

**种属反应性:** Human


**成分:** PBS (without Mg<sup>2+</sup> and Ca<sup>2+</sup>), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

**研究领域:** Signal Transduction, Cancer, Developmental Biology

**储存和运输:** Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 221198(CFC1 Antibody) at a dilution of 1/30(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 221198(Anti-CFC1 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using 221198(Anti-CFC1 Antibody) at a dilution of 1/30.



In comparison with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with synthetic peptide and then with D262695(Anti-CFC1 Antibody) at dilution 1/30.



# Product Description

Pioneering GTPase and Oncogene Product Development since 2010

---